Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease
- PMID: 19151926
- DOI: 10.1007/s10792-008-9288-1
Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease
Abstract
Purpose: To evaluate clinical and angiographic differences in patients with Vogt-Koyanagi-Harada (VKH) disease during the early 4-month treatment phase with high- or medium-dose systemic corticosteroid therapy.
Methods: VKH patients treated at the Centre for Ophthalmic Specialized Care, Lausanne, Switzerland (n = 4), or the Department of Ophthalmology, Tokyo Medical and Dental University, Tokyo, Japan (n = 5), underwent a pre-treatment indocyanine green angiography (ICGA) and a follow-up ICGA four months after treatment began. Lausanne patients received high-dose, systemic corticosteroid therapy, with or without immunosuppressive therapy. Tokyo patients received medium-dose systemic corticosteroid therapy that included 3 days of intravenous pulse methylprednisolone. ICGA signs including choroidal stromal vessel hyperfluorescence and leakage, hypofluorescent dark dots (HDD), fuzzy vascular pattern of large stromal vessels and disc hyperfluorescence were retrospectively compared.
Results: The pre-treatment ICGA demonstrated that each of the nine patients had choroidal inflammatory foci, as indicated by HDD. At 4-month follow-up, clinical and fluorescein findings had improved almost equally in both groups. HDD had resolved in the Lausanne group but persisted in the Tokyo group. Sunset glow fundus occurred in three of the Tokyo patients and none of the Lausanne patients.
Conclusions: Submaximal doses of inflammation suppressive therapy are sufficient to suppress clinically apparent disease but not the underlying lesion process. This explains the propensity for sunset glow fundus in seemingly controlled disease.
Similar articles
-
Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up.Int Ophthalmol. 2007 Apr-Jun;27(2-3):173-82. doi: 10.1007/s10792-007-9060-y. Epub 2007 Apr 25. Int Ophthalmol. 2007. PMID: 17457515
-
Indocyanine green angiography-guided management of Vogt-Koyanagi-Harada disease: differentiation between choroidal scars and active lesions.Int Ophthalmol. 2013 Oct;33(5):571-7. doi: 10.1007/s10792-012-9692-4. Epub 2013 Jan 1. Int Ophthalmol. 2013. PMID: 23277207
-
Indocyanine green angiographic findings in initial-onset acute Vogt-Koyanagi-Harada disease.Acta Ophthalmol. 2016 Sep;94(6):573-8. doi: 10.1111/aos.12974. Epub 2016 Jan 29. Acta Ophthalmol. 2016. PMID: 26823203
-
Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.Int Ophthalmol. 2017 Dec;37(6):1383-1395. doi: 10.1007/s10792-016-0395-0. Epub 2016 Nov 14. Int Ophthalmol. 2017. PMID: 27844182 Free PMC article. Review.
-
Vogt-Koyanagi-Harada disease: recurrence rates after initial-onset disease differ according to treatment modality and geographic area.Int Ophthalmol. 2020 Sep;40(9):2423-2433. doi: 10.1007/s10792-020-01417-1. Epub 2020 May 16. Int Ophthalmol. 2020. PMID: 32418076 Review.
Cited by
-
CNS diseases and uveitis.J Ophthalmic Vis Res. 2011 Oct;6(4):284-308. J Ophthalmic Vis Res. 2011. PMID: 22454751 Free PMC article.
-
Full-field electroretinogram behavior in Vogt-Koyanagi-Harada disease: a 24-month longitudinal study in patients from acute onset evaluated with multimodal analysis.Graefes Arch Clin Exp Ophthalmol. 2019 Oct;257(10):2285-2295. doi: 10.1007/s00417-019-04440-w. Epub 2019 Aug 22. Graefes Arch Clin Exp Ophthalmol. 2019. PMID: 31440820
-
Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.BMC Ophthalmol. 2024 Jun 7;24(1):238. doi: 10.1186/s12886-024-03511-9. BMC Ophthalmol. 2024. PMID: 38849758 Free PMC article.
-
Choroidal observations in Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography.Graefes Arch Clin Exp Ophthalmol. 2012 Jul;250(7):1089-95. doi: 10.1007/s00417-011-1910-7. Epub 2012 Jan 13. Graefes Arch Clin Exp Ophthalmol. 2012. PMID: 22240936
-
miRNA Landscape in Pathogenesis and Treatment of Vogt-Koyanagi-Harada Disease.Front Cell Dev Biol. 2021 May 10;9:658514. doi: 10.3389/fcell.2021.658514. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34041239 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical